Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266066 | 1.00 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2TP53TSHRHIF1A | |
| SCHEMBL7964323 | 1.00 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2TP53TSHRHIF1A | |
| SCHEMBL7966245 | 0.88 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2TP53TSHRHIF1A | |
| SCHEMBL7966244 | 0.88 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2TP53TSHRHIF1A | |
| SCHEMBL7966243 | 0.88 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2TP53TSHRHIF1A | |
| SCHEMBL10366380 | 0.84 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2TP53TSHRRAB9A | |
| SCHEMBL10368025 | 0.82 | RAB9A (0.47) | ALDH1A1SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL844653 | 0.81 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2TP53TSHRHIF1A | |
| SCHEMBL30546900 | 0.81 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2TP53TSHRHIF1A | |
| SCHEMBL4620895 | 0.81 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2TP53TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078654-A1 | ANTIBACTERIAL COMPOUNDS | VEIRULENCE LTD (GB) | 2025-04-17 | — | — | WO | disclosed |
| EP-1326833-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H LEE MOFFITT CANCER CT & RES (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1339701-B1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7135483-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060223853-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-6849632-B2 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ZABLOCKI JEFF (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
| US-6573264-B1 | Protecting skeletal muscles against damage, treating shock conditions, preserving donor tissue and organs used in transplants, treating cardiovascular diseases | CV THERAPEUTICS, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2002064576-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | THE PROCTER GAMBLE CO. | 2002-07-25 | — | — | US | disclosed |
| WO-2002032869-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| US-6376514-B1 | PIPERIDINE-DERIVED COMPOUNDS CONTAINING A QUINOLYL GROUP THAT INHIBITS P-GLYCOPROTEIN TRANSPORT PROTEIN ACTIVITY; FOR TREATING CANCER AND OTHER DISEASES | THE PROCTER & GAMBLE CO. | 2002-04-23 | — | — | US | disclosed |
| US-6242450-B1 | SUBSTITUTED PIPERIDINES | ELI LILLY AND COMPANY | 2001-06-05 | — | — | US | disclosed |
| WO-2000006082-A2 | TREATMENT OF ANXIETY DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006166-A1 | 5-HT1F ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976746-A1 | 5-HT1F antagonists | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0976747-A2 | Use of 5HT-1F receptor antagonists for treating anxiety disorders | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223853-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | ABCC1, ABCB1, ABCB11 | ALDH1A1 540/4885SMN1; SMN2 2454/4885TP53 2268/4885 |
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CPT1B, CPT1A, ALOX15 | ALDH1A1 69/4885SMN1; SMN2 1222/4885TP53 4482/4885 |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | ALDH1A1 110/4885SMN1; SMN2 1073/4885TP53 3711/4885 |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | ALDH1A1 351/4885SMN1; SMN2 2929/4885TP53 1486/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | ALDH1A1 110/4885SMN1; SMN2 1073/4885TP53 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.